Physician profile
Sarah Eplion
NPI 1427529130
$6,573.97
in general payments reported to CMS, 2019-2025
46 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $138 · 2023: $903 · 2024: $3,113 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,958 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,958.45 |
| Education | $349.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $607.87 | 2023-2025 | Talvey, Tecvayli, Darzalex |
| Shield Therapeutics INC | $514.15 | 2024 | |
| Astellas Pharma US INC | $464.17 | 2023-2025 | Padcev, Vyloy, Xospata |
| Daiichi Sankyo INC. | $436.16 | 2024-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $402.53 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $387.31 | 2023-2025 | Keytruda, Lynparza, Lenvima |
| Celgene Corporation | $369.34 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| Pfizer INC. | $296.78 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $285.57 | 2023-2025 | Reblozyl, Opdivo, Opdualag |
| Pharmacosmos Therapeutics INC. | $244.23 | 2024-2025 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $225.31 | 2023-2025 | Calquence, Enhertu, Imfinzi |
| Glaxosmithkline, LLC. | $221.66 | 2023-2025 | Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $216.65 | 2022-2025 | Hyqvia, Ninlaro |
| Incyte Corporation | $205.02 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $163.49 | 2023-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $156.33 | 2023-2025 | Loqtorzi, Udenyca |
| Seagen INC. | $153.95 | 2023-2025 | Tukysa, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $130.50 | 2023-2025 | |
| Gilead Sciences, INC. | $84.60 | 2024-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $83.19 | 2021-2024 | |
| Stemline Therapeutics INC. | $81.44 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $74.87 | 2024-2025 | Tivdak |
| Sobi, INC | $70.50 | 2023-2024 | |
| Puma Biotechnology, INC. | $67.59 | 2023-2025 | |
| Pharmaessentia USA Corporation | $52.45 | 2023-2024 | Besremi |
| Regeneron Healthcare Solutions, INC. | $51.51 | 2024-2025 | Libtayo, Lynozyfic |
| Eisai INC. | $50.30 | 2023-2025 | |
| Celltrion USA INC. | $49.03 | 2025 | Vegzelma |
| Alexion Pharmaceuticals, INC. | $43.59 | 2024 | Ultomiris |
| Beone Medicines USA, INC. | $36.35 | 2025 | Brukinsa |
| Caris Mpi, INC. | $35.38 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $33.69 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $29.32 | 2023 | Venclexta, Tecentriq |
| Tersera Therapeutics LLC | $23.76 | 2024 | Zoladex |
| Morphosys, US INC. | $23.44 | 2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.18 | 2025 | |
| Adc Therapeutics America, INC. | $23.17 | 2025 | |
| Myriad Genetic Laboratories, INC. | $21.91 | 2023 | Myrisk |
| Recordati_rare_diseases_inc. | $21.74 | 2023 | Sylvant |
| Blueprint Medicines Corporation | $20.05 | 2024 | Ayvakit |
| Blue Earth Diagnostics | $19.88 | 2025 | Posluma |
| Fennec Pharmaceuticals, INC. | $17.08 | 2024 | Pedmark |
| Aveo Pharmaceuticals, INC. | $16.31 | 2025 | |
| Rigel Pharmaceuticals, INC. | $15.50 | 2024 | Tavalisse, Rezlidhia |
| Kyowa Kirin, INC. | $14.29 | 2023 | Poteligeo |
| Iovance Biotherapeutics, INC. | $8.83 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Eplion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.